Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A randomized trial

Journal of Hepatology

Volumn 30, Issue 5, 1999, Pages 830-835

  Angulo, Paul ^a   Dickson, E Rolland ^a   Therneau, Terry M ^a   Jorgensen, Roberta A ^a   Smith, Coleman ^a   Desotel, Carolee K ^a   Lange, Stephen M ^a   Anderson, Monte L ^b   Mahoney, Douglas W ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Primary biliary cirrhosis (PBC); Ursodeoxycholic acid (UDCA)

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0033054812     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80136-6     Document Type: Article

References (28)

1. Angulo P, Lindor KD. Management of primary biliary cirrhosis and autoimmune cholangitis. Clin Liver Dis. 2:1998;333-351.
2. Poupon RE, Balkau B, Eschwege E, Poupon R, the UDCA-PBC study group . A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 324:1991;1548-1554.
3. Poupon RE, Poupon R, Balkau B, the UDCA-PBC study group . Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 330:1994;1342-1347.
4. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Martaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1994;1284-1290.
5. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1110:1996;1515-1518.
6. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
7. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 113:1997;884-890.
8. Pasha TM, Heathcote J, Cauch-Dudek K, Therneau TM, Dickson ER, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 29:1998;21-26.
9. Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med. 97:1982;351-356.
10. Nakagawa M, Colombo C, Setchell KD. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology. 12:1990;322-334.
11. Osuga T, Tanaka N, Matsuzaki Y, Aikawa T. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sci. 34:1989;49S-51S.
12. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
13. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterization of patients with a complete biochemical response to ursodeoxycholic acid. Gut. 36:1995;935-938.
14. Lacerda MA, Jorgensen RA, Lindor KD. Ursodiol therapy in primary biliary cirrhosis (PBC): enrichment correlates with biochemical improvement. [abstract] Gastroenterology. 104:1993;A933.
15. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, et al. Single or multiple dose of ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol. 25:1996;887-894.
16. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci. 34:1989;59S-65S.
17. Poupon R, Cretien Y, Poupon RE, Calmus Y, Damis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. i:1987;834.
18. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 97:1989;1268-1274.
19. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 10:1989;1-7.
20. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch [A]. 379:1978;103-112.
21. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugate bile acids in humans bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res. 28:1987;589-592.
22. Pasha TM, Jorgensen RA, Dickson ER, Therneau TM, Lindor KD. Early predictors of treatment failure in patients treated with ursodeoxycholic acid for primary biliary cirrhosis. [abstract] Gastroenterology. 110:1996;A129.
23. Poupon RE, Bonnand AM, Heathcote EJ, Lindor KD, Poupon R. Prognostic factors in ursodeoxycholic acid treated patients with primary biliary cirrhosis. [abstract] Hepatology. 26:1997;400A.
24. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology. 23:1996;1148-1153.
25. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 15:1992;677-684.
26. Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AEA, Maxwell JD, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology. 106:1994;134-142.
27. Lindor KD, Lacerda MA, Jorgensen RA, DeSotel CK, Batta AK, Salen G, et al. Relationship between biliary and serum bile acids and response to ursodeoxvcholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol. 93:1998;1498-1504.
28. Emond E, Carithers RL Jr, Luketic VA, Peters M, Zetterman RK, Garcia-Tsao G, et al. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo Clinic prognostic model. [abstract] Hepatology. 24:1996;168A.